EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Portfolio Pulse from Piero Cingari
Roundhill Investments has launched the Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM), the world's first ETF focused on GLP-1 weight loss drugs. The ETF includes significant holdings in Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO), which dominate the weight loss drug market. The market for these drugs is expected to grow significantly, potentially reaching $100 billion by 2030. Other companies like Amgen (NASDAQ:AMGN) and Viking Therapeutics (NASDAQ:VKTX) are also developing promising weight loss treatments.
May 21, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen (NASDAQ:AMGN) is developing a weight loss drug that shows better results than bariatric surgery in just four weeks, making it a potential future leader in the market.
Amgen's development of a highly effective weight loss drug positions it as a potential future leader in the growing weight loss drug market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Eli Lilly (NYSE:LLY) is a major holding in the new Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM), reflecting its dominance in the weight loss drug market.
Eli Lilly's inclusion in the OZEM ETF highlights its strong position in the weight loss drug market, which is expected to grow significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Novo Nordisk (NYSE:NVO) is a major holding in the new Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM), reflecting its dominance in the weight loss drug market.
Novo Nordisk's inclusion in the OZEM ETF highlights its strong position in the weight loss drug market, which is expected to grow significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Roundhill Investments has launched the Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM), providing dedicated exposure to transformative weight loss stocks.
The launch of OZEM provides investors with a unique opportunity to gain exposure to the growing weight loss drug market, which is expected to expand significantly.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Viking Therapeutics (NASDAQ:VKTX) is developing an oral tablet for weight loss, adding to the competitive landscape of the weight loss drug market.
Viking Therapeutics' development of an oral weight loss tablet adds to the competitive landscape and potential growth of the weight loss drug market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
NEUTRAL IMPACT
Hims & Hers Health Inc. (NYSE:HIMS) is offering generic versions of a weight loss drug, addressing supply challenges but not expected to have a material impact on the industry.
While Hims & Hers Health's offering of generic weight loss drugs addresses supply challenges, it is not expected to have a significant impact on the industry.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50